The U.S. Food and Drug Administration has cleared ten ZYN nicotine pouch flavors, at two strengths, for a narrow marketing claim, that adult smokers who completely switch to these products face lower health risks than if they kept smoking cigarettes. The order does not mean nicotine pouches are safe, nor does it approve them as tools to quit smoking altogether. It simply gives Swedish Match, the company behind ZYN, permission to market these specific products as a less harmful alternative for adults who fully abandon cigarettes.
A Category That Was Already Exploding
The timing is notable. Nicotine pouches have become one of the fastest growing nicotine categories in the world over the past few years, helped along by the fact that they produce no smoke or vapor and can be used discreetly, plus a growing sense among users that they are a cleaner way to consume nicotine. A recent World Health Organization report found that global retail sales of nicotine pouches hit 23.4 billion units in 2024, a jump of more than 50 percent over the year before. That kind of growth rate helps explain why regulators are only now catching up to a habit millions of younger nicotine users had already adopted on their own. In many respects, the FDA's decision formalizes a shift in behavior that had already happened rather than creating a new one.
The World Health Organization has also flagged that regulation is struggling to keep pace with how quickly pouches are spreading, and that companies are increasingly leaning on social media, influencers and youth-oriented marketing to sell them.
Where Pouches Fit Among Smoking Alternatives
The wider market for cigarette alternatives looks nothing like it did a decade ago. Nicotine-replacement therapies such as patches, gum and inhalers are still FDA-approved products designed specifically to help people quit, but they now sit alongside a much larger ecosystem of alternative nicotine products. Oral nicotine pouches are among the fastest growing of these, with ZYN competing against brands such as On! and VELO for leadership of the global oral nicotine market.
Vapes and disposable e-cigarettes still account for the largest share of the smoking-alternative category overall, with the U.S. market for them projected to reach $14.8 billion by 2030, even as they continue to draw scrutiny over youth use. Heated tobacco devices such as IQOS offer yet another option, warming tobacco instead of burning it, which cuts down exposure to many of the harmful chemicals produced by burning cigarettes.
Public Health Officials Are Not Celebrating
Public health bodies remain wary of nicotine pouches even as the FDA grants this narrow authorization. The World Health Organization has warned that pouches are gaining popularity fast among adolescents and young adults because of their strong youth appeal and high addiction potential, which raises the concern that products aimed at adult smokers could end up pulling in an entirely new set of users who never smoked in the first place.
The FDA's own order rests on toxicology data, consumer research and public health modeling. Based on that evidence, it issued a Modified Risk Tobacco Product, or MRTP, order covering 10 ZYN flavors at two strengths, 3 milligrams and 6 milligrams, for a total of 20 specific products. That authorization lets Swedish Match market only those products as a lower-risk option for adults who switch completely away from cigarettes.
The Fine Print Behind the Win
The designation is a significant win for the tobacco industry, but it comes with two important limits. First, it covers only those 20 specific products, not nicotine pouches as a whole. Second, the FDA's findings apply only to smokers who switch entirely to these pouches; anyone who keeps using cigarettes or vapes alongside pouches gets no such benefit, and the agency has explicitly advised people who don't use tobacco at all to stay away from nicotine pouches.
"FDA's review of modified risk products is intended to ensure that adult users have clear, science-based information about the relative harms of tobacco products, so they can make informed choices," said Bret Koplow, acting director of the FDA's Center for Tobacco Products. He added that the decision "informs adults who smoke about the lower risks associated with these products." Swedish Match is now required to track how the products are actually being used in the real world and report that data back to the FDA. The MRTP order itself is valid for five years unless it is renewed or withdrawn before then.
No Tobacco Product Is a Safe One
The FDA's underlying message is fairly narrow: adult smokers who completely switch to these particular nicotine pouches are likely lowering their health risk compared with continuing to smoke cigarettes. But the agency is equally clear that no tobacco product is safe, and that quitting tobacco and nicotine altogether remains the best option for long-term health. Whether the pouch category's rapid growth ends up creating a new generation of nicotine users who never smoked to begin with is, as the agency itself suggests, a separate question that this ruling does not answer.
